Delhi HC relief to Intas- stops two pharma companies from violating trademark of LOOZ

Published On 2022-06-27 13:30 GMT   |   Update On 2022-06-27 13:30 GMT

The Delhi High Court has permanently restrained two pharmaceutical manufacturers from using the trademark 'LOOZOUT' in their products, which is deceptively similar to the registered trademark 'LOOZ'.A single bench of Justice Jyoti Singh, while dealing with the suit moved by Intas Pharmaceuticals, also imposed a cost of Rs two lakh to the defendant companies.As per the recently passed order,...

Login or Register to read the full article

The Delhi High Court has permanently restrained two pharmaceutical manufacturers from using the trademark 'LOOZOUT' in their products, which is deceptively similar to the registered trademark 'LOOZ'.

A single bench of Justice Jyoti Singh, while dealing with the suit moved by Intas Pharmaceuticals, also imposed a cost of Rs two lakh to the defendant companies.

As per the recently passed order, apart from permanently restraining them from manufacturing, selling, offering for sale, advertising, and promoting the products using the mark 'LOOZOUT', they are also stopped from manufacturing and selling products under any other mark, which is identical or deceptively similar to the registered mark of the Plaintiff 'LOOZ'.

For more details, check out the full story on the link below:     

Delhi HC Relief To Intas- Stops Two Pharma Companies From Violating Trademark Of LOOZ

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News